Date
Attendees
| Committee Member | Present | Absent |
|---|---|---|
| X | ||
| X | ||
| X | ||
| X | ||
| Debbie Knapp | X | |
| Toby Hecht | X | |
| X |
Goals
- Discuss updates to ICDC and define emerging strategies and priorities
SharePoint Site
https://nih.sharepoint.com/sites/NCI-CBIIT-FNL-ICDC-ICDCLeadershipGroups
Outstanding Action Items
- Kuffel, Gina (NIH/NCI) [C] to send email to Debbie about importance of review article.
Agenda
| Item | Who | Talking Points |
|---|---|---|
| DGAB Updates |
| |
| BPSC Updates |
| |
| June Steering Committee Updates |
| |
| ICDC Site Updates |
| |
| ICDC Next Phase Planning |
|
Minutes (Not Verbatim)
Toby- Understanding of RFI is to go out ask for people doing comparative oncology across humans and dogs research to come up with questions or case studies or hypotheses that can leverage data in the ICDC to answer these question to expose gaps of data to inform the type of data we would like to source in the future.
DK- To identify key questions and if ICDC can help to answer these questions.
Toby- Who will be the PoC? I will do an outline of this and then circulate to this to the Executive Team.
JO - Executive TEam and then polish for broader dissemination to the Steering Committee.
Toby- We can send out to the Cancer Centers
AL - We can encourage all to share broadly
Previous ICDC Use Cases from Steering Committee
1. Genomic correlates across platforms (DNA, RNA, protein).
2. Correlating multi-omics data with clinical annotation and phenotypes, particularly outcomes.
3. Comparative analyses of canine and human. Examples include:
1. Search for conserved mutations between canine and human tumors
2. Disease diagnosis (e.g. cancer type) and classification mapping between canines and humans
5. Gene expression changes and mutational profiles associated with therapeutic response and outcome
6. How do sporadic tumors in non-human mammals compare to sporadic human tumors?
7. Correlations and model building from radiomic and pathomic features extracted from medical and histopathologic images with outcomes and genomics, as is currently being widely done with human images
8. Develop biomarkers of response and resistance in humans by analyzing the responses and genomic signatures in dogs.
Previous Meeting Minutes (Not Verbatim)
Toby - Can canine bladder cancer be a good model for invasive human bladder cancer? Maybe running differential expression in dogs at various stages vs. human data at different stages of disease obtained from the GDC and then comparing expression patterns and gene signatures. Real focus is comparative genomics.
Ralph - Possibly raise as a discussion point to the SC. Does this cancer in both species survive therapy to resist disease using same pathways? Is there biological convergence?
Toby - Look at dogs in ICDC and see what the genes are in dogs that are more resistant to glioma vs. dogs that are not and see if those up or down regulated genes have human homologs.
Toby - Real data in ICDC can now be used to answer real biological questions.
Ralph - Will put use case into SC meeting agenda.
Action item
- Toby to work on outline for RFI
